## **Caitlin E Mills**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3644689/publications.pdf Version: 2024-02-01



**CAITLIN F MILLS** 

#	Article	IF	CITATIONS
1	The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. Cell Systems, 2018, 6, 13-24.	6.2	327
2	A single-cell landscape of high-grade serous ovarian cancer. Nature Medicine, 2020, 26, 1271-1279.	30.7	267
3	Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell Chemical Biology, 2019, 26, 1067-1080.e8.	5.2	151
4	Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chemical Biology, 2019, 26, 792-803.e10.	5.2	103
5	A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. Cell Systems, 2019, 9, 35-48.e5.	6.2	95
6	Development and Characterization of a Wee1 Kinase Degrader. Cell Chemical Biology, 2020, 27, 57-65.e9.	5.2	68
7	The Kinase Chemogenomic Set (KCCS): An Open Science Resource for Kinase Vulnerability Identification. International Journal of Molecular Sciences, 2021, 22, 566.	4.1	62
8	Development of CDK2 and CDK5 Dual Degrader TMXâ€2172. Angewandte Chemie - International Edition, 2020, 59, 13865-13870.	13.8	47
9	Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology, 2022, 24, 316-326.	10.3	34
10	Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. Cell Systems, 2020, 10, 66-81.e11.	6.2	26
11	Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity. Cancer Research, 2020, 80, 798-810.	0.9	22
12	Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. Cell Chemical Biology, 2020, 27, 1229-1240.e4.	5.2	19
13	Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in <i>TP53-</i> and <i>BRCA1</i> -Deficient Cells. Cancer Research, 2021, 81, 2774-2787.	0.9	17
14	Integrating multi-omics data reveals function and therapeutic potential of deubiquitinating enzymes. ELife, 0, 11, .	6.0	16
15	A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC) Journal of Clinical Oncology, 2017, 35, 1030-1030.	1.6	10
16	Development of CDK2 and CDK5 Dual Degrader TMXâ€⊋172. Angewandte Chemie, 2020, 132, 13969-13974.	2.0	2
17	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi140-vi141.	1.2	0